Seagen Inc.
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates
Last updated:
Abstract:
Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5. ##STR00001##
Status:
Grant
Type:
Utility
Filling date:
25 Jun 2021
Issue date:
28 Jun 2022